PRAX Falls 12% After Trial Setback Following Analyst Boost
Praxis Precision Medicines dropped 12% after-hours following a trial setback, just three days after analysts issued upgrades projecting 91% upside. With no revenue, $305 million in annual cash burn, a
PRAX Falls 12% After Hours on New Trial Setback
NEW YORK, September 12 —
Praxis Precision Medicines, Inc. (PRAX) dropped 12% after hours on a trial setback just three days after analysts issued price target hikes projecting upside as high as 100%, a timing gap that now forces a cleaner question: whether two pending FDA decisions, with no commercial revenue and $305 million in annual cash burn, can hold a $9.34 billion market cap.
- Analyst consensus target: $638.68 vs. current price $334.58, implying ~91% upside before the after-hours decline.
- Cash runway: $760 million against $305 million annual operating outflow, roughly 2.5 years at current pace.
- Short interest at 13.4% of float signals the market was already split on this thesis before the setback.
Two NDAs Carry the Entire Weight
Praxis is a clinical-stage CNS drug developer with 168 employees, no commercial revenue, and a pipeline built around neuronal excitation-inhibition disorders. Its two NDA programs, ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, now bear the full weight of that $9.34 billion valuation. The trial setback redirecting retail attention toward those NDAs does not add a catalyst; it removes one. Praxis had been burning through capital at a pace that leaves roughly 2.5 years of runway, and any approval delay compresses that cushion further. The company's quarterly EPS has been trending less negative, the most recent print of -$2.87 beat estimates by 22%, but that trajectory reflects cost discipline, not commercial inflection.
What the Insider Register Reveals
Director Jill Desimone sold 9,600 shares across 12 open-market tranches on June 24 at prices between $301.44 and $315.70, collecting roughly $3.61 million in proceeds, below the current $334.58 price, meaning she exited before a further advance. CEO Marcio Souza transferred 23,121 shares as gifts in July but made no open-market purchases. Net open-market insider activity over the past 90 days: zero buys, $3.61 million in sales. Insider ownership stands at just 0.3% of shares outstanding while institutional ownership is reported at 123.1%, an atypically elevated figure that reflects heavy borrowing and short positioning, consistent with the 13.4% short interest already embedded in the float.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PRAX | $9.3B | n/a | +727.1% |
| OLMA | $894M | n/a | +27.8% |
| KYMR | $9.5B | n/a | +143.1% |
| EWTX | $4.8B | n/a | +224.1% |
| SRRK | $6.7B | n/a | +64.6% |
| STOK | $1.9B | n/a | +24.1% |
What the Next Approval Window Decides
The two FDA decisions now function as binary events for a company with no revenue fallback. Vormatrigine remains in Phase 3 for adjunctive focal epilepsy, and elsunersen is in Phase 3 for SCN2A-DEE, providing additional pipeline depth, but neither offsets the NDA timeline risk in the near term. The analyst consensus at $638.68 was presumably built on probability-weighted approval scenarios before this setback; whether those models trimmed the failed trial or weighted it heavily determines how much of the 91% implied upside remains intact. The specific numbers to watch: any FDA action date communication on ulixacaltamide or relutrigine, and quarterly cash burn relative to the $760 million reserve. Run the free Praxis Precision Medicines, Inc. deep-dive →
Current fundamentals, valuation and filing history for Praxis Precision Medicines, Inc. (PRAX) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did PRAX stock drop 12% after hours?
Praxis Precision Medicines fell 12% after hours on a trial setback just three days after analysts had issued price target hikes projecting upside as high as 100%. The timing removed a catalyst rather than adding one, forcing investors to focus on whether two pending FDA decisions can justify the company's $9.34 billion valuation.
How much cash does PRAX have left?
The company has $760 million in cash reserves against $305 million in annual operating expenses, providing approximately 2.5 years of runway at the current burn rate. Approval delays would compress that cushion further.
What are PRAX's two main NDA programs?
The two programs are ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies. These two NDAs now carry the full weight of the company's $9.34 billion valuation, as Praxis has no commercial revenue.
What is the analyst consensus price target?
Analyst consensus target is $638.68 versus the current price of $334.58, implying approximately 91% upside to that target. That estimate was presumably built on probability-weighted approval scenarios before this setback.
Did PRAX insiders buy or sell stock recently?
Director Jill Desimone sold 9,600 shares in June for roughly $3.61 million, while CEO Marcio Souza made no open-market purchases. Over the past 90 days, net insider activity shows zero buys and $3.61 million in sales, with insider ownership at just 0.3% of shares outstanding.
Praxis Precision Medicines fell 12% after hours on a trial setback just two days after analysts issued price target hikes projecting upside as high as 100%. With two NDAs under FDA review and $305 million in annual cash burn, the question is whether the two pending approvals alone can sustain a $9.34 billion valuation.